293 related articles for article (PubMed ID: 32878011)
1. PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?
Ricci AD; Rizzo A; Bonucci C; Tober N; Palloni A; Mollica V; Maggio I; Deserti M; Tavolari S; Brandi G
Medicines (Basel); 2020 Aug; 7(9):. PubMed ID: 32878011
[TBL] [Abstract][Full Text] [Related]
2. Biliary tract cancer and genomic alterations in homologous recombinant deficiency: exploiting synthetic lethality with PARP inhibitors.
Ahn DH; Bekaii-Saab T
Chin Clin Oncol; 2020 Feb; 9(1):6. PubMed ID: 32075397
[TBL] [Abstract][Full Text] [Related]
3. Targeting BRCA and DNA Damage Repair Genes in GI Cancers: Pathophysiology and Clinical Perspectives.
Zimmer K; Kocher F; Puccini A; Seeber A
Front Oncol; 2021; 11():662055. PubMed ID: 34707985
[TBL] [Abstract][Full Text] [Related]
4. Investigational PARP inhibitors for the treatment of biliary tract cancer: spotlight on preclinical and clinical studies.
Mehta R; Wood AC; Yu J; Kim R
Expert Opin Investig Drugs; 2021 Apr; 30(4):451-461. PubMed ID: 33660569
[No Abstract] [Full Text] [Related]
5. An update on PARP inhibitors for the treatment of cancer.
Benafif S; Hall M
Onco Targets Ther; 2015; 8():519-28. PubMed ID: 25750544
[TBL] [Abstract][Full Text] [Related]
6. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
7. Emerging therapeutic modalities of PARP inhibitors in breast cancer.
Wang X; Shi Y; Huang D; Guan X
Cancer Treat Rev; 2018 Jul; 68():62-68. PubMed ID: 29870916
[TBL] [Abstract][Full Text] [Related]
8. [Abnormalities of DNA repair and gynecological cancers].
Auguste A; Leary A
Bull Cancer; 2017 Nov; 104(11):971-980. PubMed ID: 29054544
[TBL] [Abstract][Full Text] [Related]
9. Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
Parkes EE; Kennedy RD
Oncologist; 2016 May; 21(5):586-93. PubMed ID: 27022037
[TBL] [Abstract][Full Text] [Related]
10. Advances and perspectives of PARP inhibitors.
Yi M; Dong B; Qin S; Chu Q; Wu K; Luo S
Exp Hematol Oncol; 2019; 8():29. PubMed ID: 31737426
[TBL] [Abstract][Full Text] [Related]
11. BRCA1/2 testing: therapeutic implications for breast cancer management.
Tung NM; Garber JE
Br J Cancer; 2018 Jul; 119(2):141-152. PubMed ID: 29867226
[TBL] [Abstract][Full Text] [Related]
12. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
[No Abstract] [Full Text] [Related]
13. Hereditary cancer variants and homologous recombination deficiency in biliary tract cancer.
Okawa Y; Iwasaki Y; Johnson TA; Ebata N; Inai C; Endo M; Maejima K; Sasagawa S; Fujita M; Matsuda K; Murakami Y; Nakamura T; Hirano S; Momozawa Y; Nakagawa H
J Hepatol; 2023 Feb; 78(2):333-342. PubMed ID: 36243179
[TBL] [Abstract][Full Text] [Related]
14. Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study.
Golan T; Raitses-Gurevich M; Kelley RK; Bocobo AG; Borgida A; Shroff RT; Holter S; Gallinger S; Ahn DH; Aderka D; Apurva J; Bekaii-Saab T; Friedman E; Javle M
Oncologist; 2017 Jul; 22(7):804-810. PubMed ID: 28487467
[TBL] [Abstract][Full Text] [Related]
15. PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review.
Cook SA; Tinker AV
BioDrugs; 2019 Jun; 33(3):255-273. PubMed ID: 30895466
[TBL] [Abstract][Full Text] [Related]
16. DNA Damage Repair and the Emerging Role of Poly(ADP-ribose) Polymerase Inhibition in Cancer Therapeutics.
Rabenau K; Hofstatter E
Clin Ther; 2016 Jul; 38(7):1577-88. PubMed ID: 27368114
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal Cancers.
Alhusaini A; Cannon A; Maher SG; Reynolds JV; Lynam-Lennon N
Biomedicines; 2021 Aug; 9(8):. PubMed ID: 34440228
[TBL] [Abstract][Full Text] [Related]
18. PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.
Morgan RD; Clamp AR; Evans DGR; Edmondson RJ; Jayson GC
Cancer Chemother Pharmacol; 2018 Apr; 81(4):647-658. PubMed ID: 29464354
[TBL] [Abstract][Full Text] [Related]
19. Poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer.
Heitmann J; Geeleher P; Zuo Z; Weichselbaum RR; Vokes EE; Fetscher S; Seiwert TY
Oral Oncol; 2014 Sep; 50(9):825-31. PubMed ID: 25017803
[TBL] [Abstract][Full Text] [Related]
20. An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.
Chung C; Lee R
J Oncol Pharm Pract; 2017 Sep; 23(6):454-469. PubMed ID: 27357817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
